LIFE aTyr Pharma Inc.

+0.01  (+1%)
Previous Close 0.54
Open 0.53
Price To Book 0.6
Market Cap 20002104
Shares 36,500,189
Volume 50,326
Short Ratio
Av. Daily Volume 460,577

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS).
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2 patient trial to be initiated 4Q 2018.
Pulmonary sarcoidosis

Latest News

  1. aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
  2. aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
  3. Edited Transcript of LIFE earnings conference call or presentation 25-Mar-19 9:00pm GMT
  4. aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
  5. Atyr Pharma (LIFE) Upgraded to Buy: Here's Why
  6. Atyr Pharma: 4Q Earnings Snapshot
  7. aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
  8. aTyr Pharma, Inc. to Host Earnings Call
  9. aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  10. aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
  11. aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
  12. aTyr Pharma Announces Participation at March Investor Conferences
  13. aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
  14. Evolve Announces February 2019 Distributions for Evolve ETFs
  15. aTyr Pharma to Present at the BIO CEO & Investor Conference
  16. aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
  17. Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease
  18. featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger
  19. What Bargain Hunting? Tap 5 Stocks With Rising P/E
  20. aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events